-- RESEARCH ALERT-Actavis PLC <ACT.N> : Susquehanna raises target price to $200
-- 
-- Mon Jan 27, 2014 07:59AM EST
-- None



Jan 27 (Reuters) -   * Actavis Plc <ACT.N> : Susquehanna raises target price to $200 from $170;    rating neutral  * Valeant Pharmaceuticals International Inc <VRX.N> : Susquehanna raises target    price to $160 from $145; rating positive   * Teva Pharmaceutical Industries Ltd <TEVA.O> : Susquehanna raises target price to $52 from $50; rating positive  * Endo Health Solutions Inc <ENDP.O> : Susquehanna raises target price to $75    from $62; rating neutral  * Salix Pharmaceuticals Ltd <SLXP.O> : Susquehanna raises target price to $110    from $81; rating neutral  * Mylan Inc <MYL.O> : Susquehanna raises target price to $52 from $50; rating    positive  * Shire <SHPG.O> : Susquehanna raises target price to $175 from $160; rating    positive  For a summary of rating and price target changes on U.S. companies:   Reuters Eikon users, click on [RCH/US]   Reuters 3000Xtra users, double-click [RCH/US]   Thomson ONE users, type in RT/RCH/US       For a summary of rating and price target changes on Canadian companies:   Reuters Eikon users, click on [RCH/CA]   Reuters 3000Xtra users, double-click [RCH/CA]   Thomson ONE users, type in RT/RCH/CA      ((nyc.equities.newsroom@reuters.com); (Reuters Messaging: saqib.ahmed.thomsonreuters.com@reuters.net) ((Bangalore Newsroom +91 80 6749 1130; within U.S. +1 646 223 8780))

